देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
GABAPENTIN
AURO PHARMA INC
N02BF01
GABAPENTIN
300MG
CAPSULE
GABAPENTIN 300MG
ORAL
100/500/1000
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0125929003; AHFS:
APPROVED
2009-08-11
AURO-GABAPENTIN PRODUCT MONOGRAPH PAGE 1 OF 36 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-GABAPENTIN Gabapentin Capsules Capsules, 100 mg, 300 mg and 400 mg, oral Manufacturer Standard Antiepileptic Agent Submission Control No: 274658 Auro Pharma Inc. 3700 Steeles Avenue West, Suite 402 Woodbridge, Ontario, L4L 8K8, Canada Date of Initial Authorization: December 31, 2008 Date of Revision: September 29, 2023 AURO-GABAPENTIN PRODUCT MONOGRAPH PAGE 2 OF 36 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance 09/2023 7.1 Special Populations, 7.1.1 Pregnant Women, Neonatal withdrawal syndrome 09/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES.............................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ........................................................................................................................ 4 1.1 Pediatrics ................................................................................................................................. 4 1.2 Geriatrics ................................................................................................................................. 4 2 CONTRAINDICATIONS ........................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................... 4 4 DOSAGE AND ADMINISTRATION ........................................................................................... 4 4.1 Dosing Considerations ..................................................................................................... पूरा दस्तावेज़ पढ़ें